Sun Pharmaceutical Industries Limited
Stock Forecast, Prediction & Price Target

	Passed			Analyst forecast
Metric	3/31/2021	3/31/2022	3/31/2024	3/31/2026	3/31/2027
Revenue % change YoY	₹331.39B N/A	₹384.26B 15.95%	₹477.58B 24.28%	Avg: ₹589.73B Low: ₹589.73B High: ₹589.73B avg. 23.48%	Avg: ₹627.51B Low: ₹627.51B High: ₹627.51B avg. 6.40%
Net Income % change YoY	₹29.03B N/A	₹32.72B 12.70%	₹95.76B 192.61%	Avg: ₹128.00B Low: ₹112.76B High: ₹138.20B avg. 33.66%	Avg: ₹143.75B Low: ₹137.48B High: ₹152.11B avg. 12.30%
EBITDA % change YoY	₹49.98B N/A	₹116.00B 132.07%	₹138.36B 19.27%	Avg: ₹160.30B Low: ₹160.30B High: ₹160.30B avg. 15.86%	Avg: ₹170.58B Low: ₹170.58B High: ₹170.58B avg. 6.40%
EPS % change YoY	$12.1 N/A	$13.64 12.72%	$39.91 192.59%	Avg: $53.27 Low: $47 High: $57.6 avg. 33.47%	Avg: $59.64 Low: $57.3 High: $63.4 avg. 11.95%
Operating Expenses % change YoY	₹168.35B N/A	₹182.41B 8.34%	₹356.88B 95.64%	Avg: ₹106.14B Low: ₹106.14B High: ₹106.14B avg. -70.25%	Avg: ₹112.94B Low: ₹112.94B High: ₹112.94B avg. 6.40%

FAQ

Wall Street analysts estimate the annual average earnings growth rate of 22.98% in 2026-2027.

We have gathered data from 29 analysts. Their low estimate is 112.76B, average is 128.00B and high is 138.20B.

Wall Street analysts forecast annual average revenue growth of 14.94% in 2026-2027.

We have gathered data from 34 analysts. Their low revenue estimate is ₹589.73B, average is ₹589.73B and high is ₹589.73B.

Wall Street analysts forecast annual average earnings growth of 22.71% in 2026-2027.

We have gathered data from 29 analysts. Their low earnings per share estimate is $47, average is $53.27 and high is ₹57.6.